Kiora Pharmaceuticals Inc KPRX
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2015-02-13 |
| Shares Out. | 4,430,000 |
| Website | kiorapharma.com/ ↗ |
| Phone | 13026365400 |
| Employees | 13 |
| Net Income | -$2.4M |
| Free Cash Flow | -$10.5M |
| Total Assets | $21.2M |
| Total Liabilities | $7.3M |
| Equity | $13.9M |
About Kiora Pharmaceuticals Inc
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Kiora Pharmaceuticals Inc is a publicly traded company under the ticker symbol KPRX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-07-01)